Patient Background

• Risk factors: Diabetes mellitus, Dyslipidemia, Hypertension
• Prior procedures:
  • CABG in 2014: 2 grafts - LIMA to LAD and RSVG to OM2
  • Post PTCA with LAD stents (proximal and mid)
  • Post PPI (pacemaker/ICD lead in RV apex and RA)
• Echo (30/06/2026): LV function normal, concentric LVH, mildly sclerosed AV, mild AR, grade I/IV diastolic dysfunction (DD), intact septae, EF 62%

Graft Status

Native Coronary Arteries

Left Main (LMCA)

• No significant stenosis
• Bifurcates into LAD and LCX normally (Type III origin)

LAD

• Proximal and mid LAD: Long stents present - stent hypodensity causing occlusion in both proximal and mid LAD stent (in-stent occlusion)
• Distal LAD: Diffusely critically diseased with points of occlusion
• Diagonal branches: Critically diseased and occluded

LCX

• Non-dominant
• Proximal: Soft plaque with mild stenosis
• Mid segment: Focal band-like occlusion
• Distal: Points of critical stenosis
• Last OM: Diffusely diseased with points of critical stenosis
• OM2: Good-calibre vessel (graft target), proximal mild stenosis

RCA

• Dominant vessel
• Origin and course normal
• Proximal band: Mixed plaque causing 30-40% stenosis
• Rest of RCA: Mild disease only
• PDA and PLV: Mild disease, no significant stenosis

Myocardium, Pericardium, and Other

• LV: Not dilated, no LV aneurysm, no major clot
• No pericardial effusion, calcification, or thickening
• Pacemaker: 1 lead in RV apex, another lead in RA
• Lungs: No significant abnormality

Impression (Summary)

Status post-CABG (2014)

1. LIMA to LAD graft: OCCLUDED
2. Proximal and mid LAD stents: OCCLUDED (in-stent occlusion)
3. Distal LAD: Diffusely critically diseased with points of occlusion
4. RSVG to OM2: Patent - no significant stenosis in graft or distal runoff
5. Native RCA, PDA, PLV: No significant stenosis

Clinical Significance

• The LAD territory is critically ischemic: both the LIMA graft and the in-LAD stents are occluded. The distal LAD itself is also critically diseased. This means the entire anterior wall may be dependent on collateral flow.
• The LCX territory also has significant native disease (focal occlusion in mid-LCX, critical stenosis distally), though the RSVG to OM2 is functioning.
• The RCA territory is relatively preserved with only mild-moderate native disease.
• With EF still at 62%, collateral circulation is likely maintaining anterior wall viability to some degree - but this patient is at high risk for anterior MI.

This interpretation is for informational purposes only and must be correlated clinically by the treating physician.

High-Risk Management: Post-CABG with Occluded LIMA/Stents and Diffuse LAD Disease

1. Immediate Priority: Multidisciplinary Heart Team Review

• Is revascularization feasible? (Redo-CABG vs. complex PCI vs. medical therapy alone)
• The diffuse critical disease and occlusion of the distal LAD make this technically very challenging.
• Redo-CABG carries significantly higher operative risk in a 71-year-old with prior CABG, DM, and pacemaker.
• Complex PCI (CTO-PCI) of LAD territory may be attempted if adequate target vessels exist, but diffuse disease with points of occlusion throughout the entire LAD makes this high-risk with uncertain success.

2. Assess Viability Before Any Revascularization Decision

• Cardiac MRI or Nuclear Perfusion Imaging (PET/SPECT): Assess whether the LAD territory myocardium is viable (hibernating) or infarcted. Only viable myocardium benefits from revascularization.
• Stress imaging: Quantify ischemic burden. Per ISCHEMIA trial data (systematic review, PMID 38492177), in stable CAD with preserved EF, optimal medical therapy (OMT) alone is not inferior to revascularization for hard outcomes - but this patient's anatomy (total LAD occlusion with collateral dependence) is more extreme than the average ISCHEMIA patient.

3. Guideline-Directed Medical Therapy (GDMT) - Non-Negotiable Regardless of Revascularization

A. Antiplatelet Therapy

• Given the RSVG to OM2 is the only patent graft, aspirin + clopidogrel (DAPT) is a reasonable choice to preserve that graft.

B. Lipid-Lowering (Very Aggressive Target)

• This patient qualifies for a PCSK9 inhibitor under current guidelines given multiple ASCVD events and the severity of disease. Evolocumab trial evidence (PMID 41903215) supports benefit in high-risk diabetic patients.

C. Beta-Blocker

• Continue or start Metoprolol succinate (already on Metoprolol per the report).
• Target resting HR 55-65 bpm - reduces ischemic burden, anti-arrhythmic benefit.

D. ACE Inhibitor or ARB

• Class I in patients with CAD + diabetes + hypertension. Start if not already on one.
• Target BP < 130/80 mmHg.

E. Anti-Anginal Therapy (for symptom control)

F. Diabetes Management

• Target HbA1c < 7% (or individualized given age 71 and comorbidities).
• SGLT2 inhibitor (Empagliflozin/Dapagliflozin): Class I in CCD + DM - provides cardiovascular mortality benefit independent of glucose lowering.
• Avoid hypoglycemia-inducing regimens (hypoglycemia is a trigger for ischemic events).

G. Anticoagulation

• No routine anticoagulation unless AF is present or prosthetic valve indication.

4. Revascularization Decision Framework

5. Device Therapy Assessment

• ICD: With EF currently 62%, primary prevention ICD is not yet indicated. However, if the anterior wall undergoes further infarction and EF drops to <35%, reassess.
• Pacemaker check: Patient already has a device (lead in RV apex and RA) - ensure optimal programming, avoid unnecessary RV pacing.

6. Cardiac Rehabilitation

• Class I indication post-CABG and in high-risk CCS.
• Meta-analysis of 63 RCTs showed a 26% reduction in cardiovascular mortality (RR 0.74) and 18% reduction in hospitalizations with cardiac rehab vs. usual care. (Fuster & Hurst's The Heart, 15th Ed.)
• Supervised exercise, dietary counseling, psychosocial support.

7. Monitoring and Follow-Up

Summary Priority List

1. Heart Team MDT discussion today - is PCI/redo-CABG feasible?
2. Viability imaging (cardiac MRI or PET) - only if revascularization is being considered
3. Intensify OMT - maximize aspirin + DAPT, high-intensity statin, add ezetimibe ± PCSK9i, start SGLT2i, optimize BP and HR
4. Add Ranolazine if symptomatic ischemia persists despite GDMT
5. Cardiac rehabilitation referral
6. Patient education on warning signs requiring emergency attendance (EMERGENCY 1066 at Apollo)

This patient's only remaining functional graft (RSVG to OM2) must be protected at all costs. Any intervention carrying risk to that graft could be catastrophic.